Prevention & lipids

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model

Eur Heart JPublished Risk prediction model development and external validation study

Authors' conclusion

The updated SMART-REACH2 model accounts for geographical and sex-specific variations and allows estimation of short-term and lifetime risk of recurrent CV events and treatment benefits, facilitating shared decision-making as recommended by guidelines.

Study context

Population
Patients aged 40–90 years with established atherosclerotic CVD (coronary, cerebrovascular, PAD and/or AAA)derivation
Participants
8,708 patients
Outcome
Recurrent CV events (MI, stroke or CV death); model performance by calibration and Harrell's C-statistic
Methodological detailssex-stratified cause-specific Cox models, recalibration to risk regions
  • Sex-stratified cause-specific Cox models
  • Recalibration to risk regions

Performance

As reported in the abstract

Discrimination in external validation (Harrell's C-statistic)

Pooled C-statistic

0.68

95% CI 0.66–0.69

C-statistic, European low-risk region (0.64-0.69)

0.66

C-statistic, Latin America (0.66-0.78)

0.72

Further findings

Derivation cohort recurrent cardiovascular (CV) events · median follow-up 8.5 years (25th-75th: 4.3-13.0)

Recurrent CV events
2057

Performance by sex and CVD subtype

Performance consistent across sexes and CVD subtypes

Estimated gain in CVD-free life expectancy with intensified prevention (15 mmHg SBP and 1.0 mmol/L LDL-C reduction), 50-year-old example patient

Years

Low-risk region
2
Very-high-risk region
4.4

Original publication

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model. Eur Heart J. Published 5 June 2026. doi:10.1093/eurheartj/ehag400

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.